Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” by Karthikeyan Veeraraghavalu, Can Zhang, Sean.

Slides:



Advertisements
Similar presentations
Comment on “ApoE-Directed Therapeutics Rapidly Clear β- Amyloid and Reverse Deficits in AD Mouse Models” by Ina Tesseur, Adrian C. Lo, Anouk Roberfroid,
Advertisements

Fig. 1 Anti-inflammatory drug treatment reduces the number of reactive microglia in the hippocampus of APPV717I mice. APPV717I transgenic mice (10 months.
NPT088 reduces both amyloid-β and tau pathologies in transgenic mice
Figure 1 Body weight of control and BPA-treated mothers after delivery
Biphasic Alteration of the Inhibitory Synapse Scaffold Protein Gephyrin in Early and Late Stages of an Alzheimer Disease Model  Eva Kiss, Karin Gorgas,
Fig. 2. Increased Aβ plaque load in 16-month-old APP/PS1;C3 KO mice.
Volume 82, Issue 1, Pages (April 2014)
Volume 90, Issue 5, Pages (June 2016)
Volume 21, Issue 2, Pages e5 (August 2017)
ApoE Promotes the Proteolytic Degradation of Aβ
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Depletion of primary cilia in articular chondrocytes results in reduced Gli3 repressor to activator ratio, increased Hedgehog signaling, and symptoms.
Fig. 5. Wisper is associated with TIA1-related protein and regulates lysyl hydroxylase 2 expression. Wisper is associated with TIA1-related protein and.
Analysis of brain and spinal cord of treated Gaa−/− mice and controls
Volume 8, Issue 1, Pages (January 2017)
Fig. 4. Prion infectivity of skin samples from sCJD patients.
Volume 30, Issue 3, Pages (May 2001)
Volume 59, Issue 4, Pages (August 2008)
Molecular Therapy - Nucleic Acids
by Soyon Hong, Victoria F. Beja-Glasser, Bianca M
Fig. 1. Aberrant JNK pathway activation in mouse models of ALS and in spinal cord tissue from patients with sporadic ALS. Aberrant JNK pathway activation.
Volume 95, Issue 2, Pages e6 (July 2017)
ApoE4 Accelerates Early Seeding of Amyloid Pathology
by Melissa R. Miller, Nadja Mannowetz, Anthony T
by Ling-juan Zhang, Christian F. Guerrero-Juarez, Tissa Hata, Sagar P
Fig. 1. Muscles of LAMA2 MD patients and dyW/dyW mice contain high amounts of laminin-α4 and show deficits in BM. Muscles of LAMA2 MD patients and dyW/dyW.
Volume 49, Issue 5, Pages (March 2006)
Volume 78, Issue 4, Pages (May 2013)
Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” by Ashleigh R. Price, Guilian Xu, Zoe B. Siemienski,
Fig. 4. Plaque-associated microglia and astrocytes and brain cytokines were altered in APP/PS1;C3 KO mice compared to APP/PS1 mice. Plaque-associated microglia.
Volume 85, Issue 3, Pages (February 2015)
Age‐related amyloid deposition in APPPS1‐21 mice.
Nec‐1 inhibits the phosphorylation and aggregation of tau
EPS15L1 is predominantly expressed in neurons and surviving Eps15L1-KO mice have development and neural deficits. EPS15L1 is predominantly expressed in.
Volume 71, Issue 5, Pages (September 2011)
Elysse C. Filipe et al. BTS 2018;3:38-53
The absence of the centrosome changes global microtubule dynamics in a migrating cell. The absence of the centrosome changes global microtubule dynamics.
Volume 20, Issue 13, Pages (September 2017)
BDNF expression in the cerebellum and brain stem region.
Volume 4, Issue 1, Pages (July 2013)
Volume 64, Issue 5, Pages (December 2009)
Volume 4, Issue 1, Pages (July 2013)
Fig. 3. Morphological changes associated with glial activation were reduced in 16-month-old APP/PS1;C3 KO mice. Morphological changes associated with glial.
Volume 17, Issue 5, Pages (May 2009)
Target engagement of the systemic Stat3 inhibitor in APP/PS1 mice
Increased Expression of Wnt2 and SFRP4 in Tsk Mouse Skin: Role of Wnt Signaling in Altered Dermal Fibrillin Deposition and Systemic Sclerosis  Julie Bayle,
Fig. 3 CSF1 is expressed in human melanoma.
Fig. 6 Combination therapy with LVSOD2 and LVshCTGF preserves flap volume and reduces fibrosis after RT. Combination therapy with LVSOD2 and LVshCTGF preserves.
Amyloid pathology in APP/PSEN1 and APP/PSEN1/APOEnull mice.
Volume 90, Issue 3, Pages (May 2016)
Volume 71, Issue 5, Pages (September 2011)
Volume 17, Issue 3, Pages (October 2016)
Fig. 2. Ex vivo inducible knockout of PDCD2 in ESCs results in loss of S phase entry and increased p53.(A) Growth curve of inducible knockout and WT ESCs.
Volume 23, Issue 8, Pages (August 2015)
Oral administration of CX-4945 suppresses Tau phosphorylation in DYRK1A-overexpressing mice. Oral administration of CX-4945 suppresses Tau phosphorylation.
5-Azacytidine-induced DNA demethylation partially inhibits Aur-B driven phosphorylation of histone H3 at pericentromeres in interphase nuclei. 5-Azacytidine-induced.
Volume 49, Issue 4, Pages (February 2006)
Fig. 2. Deficiency of neuronal HS leads to reduced neuroinflammation.
Fig. 2. Acetylation stiffens primary cilia.
Fig. 5. Anti-inflammatory effects of silibinin on KA treatment in the hippocampus. (A) Representative coronal sections of the hippocampal CA1 region following.
Accumulation of β-amyloid deposits assessed by immunohistochemistry in E3FAD and E4FAD mice across dietary treatments. Accumulation of β-amyloid deposits.
Ctip2 directly regulates Notch1 expression in differentiated cells.
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
Fig. 3. Morphological changes associated with glial activation were reduced in 16-month-old APP/PS1;C3 KO mice. Morphological changes associated with glial.
TOMA does not affect NFTs in posterior hypothalamus or cortex.
Fig. 6. Microglial phagocytosis and lysosomal uptake of Aβ induced by SUS treatment. Microglial phagocytosis and lysosomal uptake of Aβ induced by SUS.
Microfluidic platform for cell phenotype and gene function analysis
Pioglitazone induces the clearance of amyloid in APP/PS1 mice.
Fig. 3. HERV-K–induced neuronal toxicity in vivo.
Foxo3 is expressed in the adult mouse cochlea.
Presentation transcript:

Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” by Karthikeyan Veeraraghavalu, Can Zhang, Sean Miller, Jasmin K. Hefendehl, Tharinda W. Rajapaksha, Jason Ulrich, Mathias Jucker, David M. Holtzman, Rudolph E. Tanzi, Robert Vassar, and Sangram S. Sisodia Science Volume 340(6135):924-924 May 24, 2013 Published by AAAS

Fig. 1 Effects of Targretin on amyloid plaque burden and Aβ levels in APP/PS1 mice. Effects of Targretin on amyloid plaque burden and Aβ levels in APP/PS1 mice. Representative images of hemibrain sections from 6-month-old APP/PS1 mice treated with vehicle (A) or 100 mg/kg Targretin (D) that were immunostained with 3D6 antibody. Scale bar, 500 μm. (B) and (E) Representative confocal z-stack projection images of Iba1+ microglia (green) surrounding 3D6+ amyloid plaque deposits (red) in sections from vehicle-treated (B) or Targretin-treated (E) animals. (C and F) Overlay and orthogonal views (XY/XZ sectional) of images shown in (B) and (E), respectively. Arrows point to the intracellular 3D6 immunoreactivity in microglia of both sample groups. These results suggest that microglial phagocytosis of Aβ is not enhanced in Targretin-treated animals. Scale bar, 25 μm. Sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (G and H) Histograms show the amyloid plaque area fraction and the total number of plaques in cortex (CX) or hippocampus (HP), respectively. No significance was observed in the plaque area fraction (P = 0.122 in cortex; P = 0.234 in hippocampus) or total plaque numbers (P = 0.174 in cortex; P = 0.183 in hippocampus) between the treatment groups. Total areas examined in vehicle- versus Targretin-treated groups are comparable (194338.4 ± 5592.096 μm2 for vehicle group versus 192936 ± 5131.078 μm2 for Targretin group, in cortex with P = 0.437; 87837.57 ± 3391.043 μm2 for vehicle group versus 89502.69 ± 5258.606 μm2 for Targretin group, in hippocampus with P = 0.412). Six sections representing every sixth or twelfth coronal serial section spanning the proximal to distal end of hippocampus, including the cortical regions, were examined to quantify amyloid area fraction and plaque numbers using Image J Foci dMacro and Analyze particles plug-in by applying uniform image threshold. (I) Histograms show fold changes in soluble (s) Aβ40 (*P = 0.279; Cohen’s d: 0.605), formic acid-extractable insoluble (ins) Aβ40 (#P = 0.359; Cohen’s d: 0.509), soluble Aβ42 ($P = 0.247; Cohen’s d: 0.64), and insoluble Aβ42 (%P = 0.676; Cohen’s d: 0.22) after normalization against total protein content. (J) Representative Western blots of detergent-soluble total protein lysates (60 μg loaded in each lane) from hemibrains of vehicle- or Targretin-treated animals probed with antibodies to ABCA1 or β-III tubulin. (K) Quantification of ABCA1 band intensity normalized against β-III tubulin levels (*P < 0.001). Data in (G), (H), (I), and (K) represent mean ± SEM; N = 7 mice per group). Karthikeyan Veeraraghavalu et al. Science 2013;340:924 Published by AAAS

Fig. 2 Effects of Targretin on amyloid plaque burden and Aβ levels in 5X FAD and APPPS1-21 mice. Effects of Targretin on amyloid plaque burden and Aβ levels in 5X FAD and APPPS1-21 mice. (A to G) Representative images of hemibrain sections from 3- to 4-month old 5XFAD mice treated with vehicle (A) or 100 mg/kg Targretin (B) for 7 days that were immunostained with 3D6 antibody. Scale bar, 500 μm. (CandD) Histograms show the amyloid plaque area fraction and the total number of plaques in cortex (CX) or hippocampus (HP), respectively. Total area examined in vehicle- versus Targretin-treated groups are comparable (117841.3 ± 3303.082 μm2 for vehicle group versus 107086.3 ± 6802.094 μm2 for Targretin group, in cortex with P = 0.17; 67039.59 ± 4030.787 μm2 for vehicle group versus 70535.3 ± 2843.477 μm2 for Targretin group, in hippocampus with P = 0.486). (E) Histogram shows fold changes in soluble (s) Aβ40 (*P = 0.008; Cohen’s d: 1.25), insoluble (ins) Aβ40 (#P = 0.292; Cohen’s d: 0.46), soluble Aβ42 ($P = 0.102; Cohen’s d: 0.73), and insoluble Aβ42 (%P = 0.363; Cohen’s d: 0.396) levels after normalization against total protein content. (F) Representative Western blots of detergent-soluble total protein lysates (60 μg per lane) from hemibrains of vehicle- or Targretin-treated 5XFAD animals using antibodies to ABCA1 or β-III tubulin. (G) Quantification of ABCA1 band intensity normalized against β-III tubulin levels (*P = 0.004). Data in (C), (D), (E) and (G) represent mean ± SEM; N = 11 mice per group. (H to M) Amyloid plaque burden is not reduced in 9-month-old APPPS1-21 mice after 26 days of 100 mg/kg per day Targretin treatment. Representative images of hemibrain sections from 9-month-old APPPS1-21 mice treated with vehicle (H2O) (H) or 100 mg/kg Targretin (I) for 26 days that were immunostained with Aβ-specific CN3 antibody. Scale bar, 500 μm. (J) Histogram shows the percentage of amyloid plaque load assessed in neocortex on random sets of every 12th systematically sampled 40-μm-thick sections, analyzed by area fraction technique estimated with the aid of Stereologer software (mean ± SEM; N = 4 mice per group). (K) Histogram shows fold changes in soluble (s) Aβ40 (*P = 0.269; Cohen’s d: 0.32), insoluble (ins) Aβ40 (#P = 0.49; Cohen’s d: 0.013), soluble Aβ42 ($P = 0.182; Cohen’s d: 0.325), and insoluble Aβ42 (%P = 0.495; Cohen’s d: 0.008) levels in vehicle- versus Targretin-treated APPPS1-21 mice, respectively. (L) Representative Western blots of detergent-soluble total protein lysates (60 μg per lane) from hemibrains of vehicle- or Targretin-treated APPPS1-21 mice using antibodies to ABCA1 or β-III tubulin. (M) Quantification of ABCA1 band intensity normalized against β-III tubulin levels (*P = 0.04). Data in (K) and (M) represent mean ± SEM; N = 3 mice per group). Karthikeyan Veeraraghavalu et al. Science 2013;340:924 Published by AAAS